| Nov 16 |
Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Sep 11 |
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
|
| Sep 3 |
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 17 |
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
|
| Jul 29 |
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
|
| Jul 16 |
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
|
| May 29 |
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
|
